Research Summary
In 2024, PharmaGen Technologies initiated a Phase III clinical trial for BX-301, a novel immunotherapy targeting metastatic melanoma.
The research was led by Dr. Sarah Chen, Chief Scientist at the Stanford Oncology Center in California. The study enrolled 450 patients across 23 sites in the United States and Europe.
BX-301 works by targeting the PD-1 receptor, blocking the interaction between PD-1 and its ligand PD-L1. This mechanism allows T-cells to recognize and destroy cancer cells more effectively.
The trial demonstrated a 38% overall response rate, with a median progression-free survival of 8.2 months. The results were published in The New England Journal of Medicine on March 15, 2025.
Common adverse effects included fatigue (42%), nausea (28%), and skin rash (15%). Serious immune-related adverse events occurred in 8% of patients.